During direct laryngoscopy and tracheal intubation for a patient with a temporal lobe tumor, which drug is most appropriate to control systemic arterial blood pressure?

During direct laryngoscopy and tracheal intubation for a patient with a temporal lobe tumor, which drug is most appropriate to control systemic arterial blood pressure?

• A. Esmolol
• B. Nitroglycerine
• C. Hydralazine
• D. Isoflurane

Answer: (A)

During direct laryngoscopy and intubation, a notable surge in sympathetic activity can cause a rapid rise in blood pressure and heart rate. In a patient with a temporal lobe tumor, this pressor response is especially hazardous because increases in mean arterial pressure can translate into higher cerebral blood flow and elevated intracranial pressure, risking brain edema or herniation. The goal is to blunt that response without causing large swings in blood pressure or affecting cerebral blood vessels. Esmolol is ideal here because it is a very short-acting beta-1 selective blocker. It quickly blunts the heart rate and reduces the blood pressure response to laryngoscopy, stabilizing hemodynamics right when the airway is being manipulated. Its rapid onset and brief duration allow precise control and quick recovery if blood pressure becomes too low or if the procedure proceeds without complication. Importantly, it minimizes changes in cerebral vasculature and intracranial dynamics compared with agents that cause vasodilation or reflex changes. Nitroglycerine and hydralazine are potent vasodilators that can provoke reflex tachycardia and, in the context of an intracranial mass, may worsen intracranial dynamics. Isoflurane, a volatile anesthetic, tends to increase cerebral blood flow and intracranial pressure, which is undesirable in a patient with a brain tumor. That makes esmolol the best option to control the pressor response during intubation in this neurofocused scenario.

During direct laryngoscopy and intubation, a notable surge in sympathetic activity can cause a rapid rise in blood pressure and heart rate. In a patient with a temporal lobe tumor, this pressor response is especially hazardous because increases in mean arterial pressure can translate into higher cerebral blood flow and elevated intracranial pressure, risking brain edema or herniation. The goal is to blunt that response without causing large swings in blood pressure or affecting cerebral blood vessels.

Esmolol is ideal here because it is a very short-acting beta-1 selective blocker. It quickly blunts the heart rate and reduces the blood pressure response to laryngoscopy, stabilizing hemodynamics right when the airway is being manipulated. Its rapid onset and brief duration allow precise control and quick recovery if blood pressure becomes too low or if the procedure proceeds without complication. Importantly, it minimizes changes in cerebral vasculature and intracranial dynamics compared with agents that cause vasodilation or reflex changes.

Nitroglycerine and hydralazine are potent vasodilators that can provoke reflex tachycardia and, in the context of an intracranial mass, may worsen intracranial dynamics. Isoflurane, a volatile anesthetic, tends to increase cerebral blood flow and intracranial pressure, which is undesirable in a patient with a brain tumor. That makes esmolol the best option to control the pressor response during intubation in this neurofocused scenario.